Close

Rebel Capital 2.0 Corp. Announces Proposed Qualifying Transaction

CALGARY, Alberta, Sept. 30, 2019 (GLOBE NEWSWIRE) — Rebel Capital 2.0 Corp. (“Rebel” or the “Corporation”) is pleased to announce that it has entered into a letter of intent with Alzex BioMedical Inc. (“Alzex”) dated September 30, 2019 (the “Letter of Intent”) in respect of a proposed transaction pursuant to which Alzex is expected to acquire Rebel by way of reverse takeover (the “Qualifying Transaction”). It is currently anticipated that the Qualifying Transaction will occur as a share exchange whereby all the issued and outstanding shares of Alzex will be exchanged for shares of Rebel on a one-for-one basis resulting in Alzex becoming a wholly-owned subsidiary of Rebel, the final structure of the Qualifying Transaction being subject to receipt of tax, corporate and securities law advice for both Rebel and Alzex. Upon completion of the Qualifying Transaction, the combined entity (the “Resulting Issuer”) will continue to carry on the business of Alzex.

UPDATE – Rebel Capital 2.0 Corp. Enters Into Definitive Agreement With Alzex Biomedical Group Inc.

CALGARY, Alberta, Jan. 07, 2020 (GLOBE NEWSWIRE) — Rebel Capital 2.0 Corp. (“Rebel” or the “Corporation”) (TSXV: RBZ.P) is pleased to announce that it has entered into a definitive agreement dated January 3, 2020 (the “Definitive Agreement”) with Alzex Biomedical Group Inc. (“Alzex”), a privately held corporation existing under the provisions of the Business Corporations